Tweet
LONDON (Reuters) - A first-in-class drug from Amgen based on a tumour-killing virus was given a green light by European regulators on Friday, paving the way for its approval within a couple of months.
More...
More...
Hi All
For those boardites who are facebook we have a Boardite Facebook Group. Be sure to check it out.